Skip to main content
Clinical Trials/NCT03133286
NCT03133286
Completed
Not Applicable

Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)

DxTerity Diagnostics2 sites in 1 country16 target enrollmentApril 6, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Radiation Therapy
Sponsor
DxTerity Diagnostics
Enrollment
16
Locations
2
Primary Endpoint
Obtain pre- and post-irradiation participant-collect blood samples
Status
Completed
Last Updated
last year

Overview

Brief Summary

Collect blood samples and associated clinical data prior to, during, and post radiation treatment.

Detailed Description

In order to further refine and independently validate the performance of DxTerity's test developed during the previous pilot study, the study will collect pre-, during, and post-irradiation blood samples and associated clinical and self-reported information from up to five hundred (500) subjects for analysis. Patients with a diagnosis of primary gastrointestinal (GI), genitourinary (GU), or gynecological (GYN) cancer requiring radiation treatment to the primary disease site will be included in the study. Combining chemotherapy is allowed. Blood samples for this study will be collected from cancer patients scheduled to undergo radiation therapy prior to and either during or after treatment. Approximately 150μL of blood per time point will be obtained via fingerstick remotely, from the participant's home or doctor's office; participation in this study will not affect any aspect of patient treatment. Samples will be collected using DxTerity's proprietary DxCollect® MCD Fingerstick Kit (MCD).

Registry
clinicaltrials.gov
Start Date
April 6, 2017
End Date
February 25, 2020
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
DxTerity Diagnostics
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male and female patients age 18 or older
  • Have a permanent address in the United States for the duration of the study
  • Diagnosed with a primary gastrointestinal (GI), genitourinary (GU), or gynecological (GYN) cancer
  • Planned radiation therapy to the abdominal/pelvic area as part of clinical care
  • Able to provide informed consent

Exclusion Criteria

  • Receipt of radiation within three (3) months to abdominal/pelvic area prior to scheduled start of Radiation Treatment

Outcomes

Primary Outcomes

Obtain pre- and post-irradiation participant-collect blood samples

Time Frame: 1.5 years

Obtain pre-irradiation participant-collected blood sample and associated clinical data from cancer patients undergoing abdominal/pelvic radiation therapy as part of clinical care.

Study Sites (2)

Loading locations...

Similar Trials